Top Story Today
A 100% Tariff on Imported Brand-Name Drugs (With a Choose-Your-Own-Adventure Escape Plan)
The Trump administration slapped a 100% tariff on imported brand-name drugs, the steepest Section 232 rate ever applied to a single product category. But the headline number is a ceiling, not a blanket. Companies that commit to building U.S. factories see the rate drop to 20%. Sign a Most Favored Nation pricing deal with HHS (matching your lowest global price for American patients), and the tariff falls to zero. Thirteen companies have already cut combined deals, with four more under negotiation, pledging approximately $400 billion in domestic manufacturing. Generics and biosimilars are completely exempt, at least for now.
Why it matters: This isn't just trade policy. It's industrial policy, price control policy, and pharmaceutical reshoring wrapped in a single proclamation, with a 2029 expiration date that ties every deal to the current presidential term.
Read more →Clinical Trials & Regulatory
The Best-Selling Drug on Earth Just Met Its First Phase 3 Copycat
Samsung Bioepis posted the first-ever Phase 3 data for a Keytruda biosimilar, and the results matched Merck's $29.5 billion juggernaut on tumor response, drug exposure, safety, and immune reactions. With at least ten competitors in the race and key U.S. patents expiring around 2028, the countdown to cheaper cancer immunotherapy is officially ticking.
Read more →BMS Built a Precision Cancer Combo. Plain Old Chemo Still Won.
In the Phase 3 KRYSTAL-10 confirmatory trial, Krazati plus cetuximab shrank colorectal tumors at nearly three times the rate of chemotherapy (47% vs. 16%), yet patients didn't live a single day longer. The trial missed both primary endpoints, putting the drug's accelerated FDA approval in jeopardy and handing the KRAS G12C colorectal space to Amgen and Roche.
Read more →Roche's Huntington's Strategy Hits Another Setback
Roche's decade-long Huntington's partnership with Ionis continues to face headwinds. The Phase 2 trial of tominersen remains ongoing and blinded, with results not expected until 2027, while the earlier Phase 3 GENERATION-HD1 trial was halted in 2021. The continued uncertainty deepens the crisis of confidence in the field's leading strategy for tackling Huntington's.
Read more →Europe Approves the First-Ever Combined Flu-COVID Vaccine
Moderna's mCOMBRIAX became the first combined flu-COVID vaccine to win regulatory approval anywhere in the world. In Phase 3 trials, the single shot actually triggered higher antibody levels than getting both vaccines separately. For a company burning cash and chasing breakeven by 2028, the EU green light opens a market analysts value at roughly $1.7 billion.
Read more →Pipeline & Discovery
Cancer's Most Famous Weapon Just Showed Up in Autoimmune Disease
Fate Therapeutics reported that all four systemic sclerosis patients treated with its off-the-shelf CAR-T therapy, FT819, showed meaningful symptom improvement. No cytokine release syndrome, no neurotoxicity, and one patient received zero conditioning chemo. It's a tiny sample, but another signal that CAR-T's second career in autoimmune disease is gaining real traction.
Read more →Moderna Launches Phase 3 Bird Flu Vaccine Trial as H5N1 Creeps Closer
Moderna began dosing the world's first Phase 3 trial of an mRNA bird flu vaccine across the U.S. and U.K., backed by $54 million from CEPI. The catch: the U.S. government pulled approximately $590 million in prior funding, so this pandemic insurance policy is running without Washington's financial support while H5N1 circulates in over 1,000 dairy herds.
Read more →Deals, Funding & Market Moves
A Gene Therapy J&J Abandoned Just Landed $400M in New Funding
MeiraGTx bought back a blindness gene therapy from J&J for $25 million (J&J had valued it at $415 million), then locked in up to $400 million in royalty-based financing from Oberland Capital. The deal covers three programs that could all file for regulatory approval within 24 months, with only $25 million in equity dilution.
Read more →Beijing Adds Semaglutide to Its Essential Drug List for 233 Million Diabetes Patients
China added semaglutide to its national reimbursement list, effective September 1, making it the second GLP-1 prioritized for the world's largest diabetes population. With core patents expired and 15 to 20 generic competitors racing to market, Novo Nordisk faces a volume bonanza at rock-bottom prices in a market projected to reach roughly $4.6 billion by 2033.
Read more →The Only Chikungunya Vaccine Got Pulled Because It Could Cause Chikungunya
Valneva withdrew IXCHIQ, the world's sole approved chikungunya vaccine, from the U.S. after over 20 serious adverse events (including 3 deaths) revealed the live-attenuated vaccine could cause the very disease it targeted. With the virus spreading northward and no replacement on American shelves, the withdrawal exposes a dangerous gap in tropical disease preparedness.
Read more →